期刊
PHARMACEUTICALS
卷 15, 期 7, 页码 -出版社
MDPI
DOI: 10.3390/ph15070848
关键词
NAPRT inhibitors; cancer metabolism; NAD; anti-cancer agents; NAMPT; NAD synthesis; in silico drug design
资金
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [17736, 22098, 19172]
- Breast Cancer Research Program (U.S. Department of Defense) [BC161452P1]
- Italian Ministry of Health [PE-2016-02362694, PE-2016-02363073]
- European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant [813284]
Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been considered as a promising anti-cancer strategy. However, current inhibitors targeting NAD-producing enzyme NAMPT have limited efficacy in clinical trials, suggesting that alternative NAD-producing enzymes may be utilized by cancer cells. Recent studies have highlighted the relevance of NAPRT as a rate-limiting enzyme in the Preiss-Handler NAD-production pathway in human cancers. In this study, a NAPRT inhibitor, 2-hydroxynicotinic acid, was found to work cooperatively with the NAMPT inhibitor FK866 to kill NAPRT-proficient cancer cells. Furthermore, two additional chemical scaffolds with NAPRT inhibitory activity were identified through high-throughput virtual screening.
Depriving cancer cells of sufficient NAD levels, mainly through interfering with their NAD-producing capacity, has been conceived as a promising anti-cancer strategy. Numerous inhibitors of the NAD-producing enzyme, nicotinamide phosphoribosyltransferase (NAMPT), have been developed over the past two decades. However, their limited anti-cancer activity in clinical trials raised the possibility that cancer cells may also exploit alternative NAD-producing enzymes. Recent studies show the relevance of nicotinic acid phosphoribosyltransferase (NAPRT), the rate-limiting enzyme of the Preiss-Handler NAD-production pathway for a large group of human cancers. We demonstrated that the NAPRT inhibitor 2-hydroxynicotinic acid (2-HNA) cooperates with the NAMPT inhibitor FK866 in killing NAPRT-proficient cancer cells that were otherwise insensitive to FK866 alone. Despite this emerging relevance of NAPRT as a potential target in cancer therapy, very few NAPRT inhibitors exist. Starting from a high-throughput virtual screening approach, we were able to identify and annotate two additional chemical scaffolds that function as NAPRT inhibitors. These compounds show comparable anti-cancer activity to 2-HNA and improved predicted aqueous solubility, in addition to demonstrating favorable drug-like profiles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据